Related Experiment Videos
[Recognizing patients at high risk for myocardial infarct]]
A von Eckardstein1, H Schulte, G Assmann
1Institut für Klinische Chemie, Universitätsspital Zürich. Arnold.voneckardstein@ikc.usz.ch
Praxis
|April 5, 2003
Summary
Antihypertensive and hypolipidemic drugs effectively prevent coronary heart disease (CHD). Guidelines recommend lowering blood pressure and LDL-cholesterol for secondary prevention and risk assessment for primary prevention.
Area of Science:
- Cardiology
- Preventive Medicine
- Pharmacology
Context:
- Established benefits of antihypertensive and hypolipidemic medications in preventing coronary heart disease (CHD).
- Current international guidelines emphasize secondary prevention strategies for patients with manifest CHD.
- Guidelines recommend specific targets for blood pressure (<140/90 mm Hg) and LDL-cholesterol (<3 mmol/l or <2.6 mmol/l).
Purpose:
- To outline current recommendations for both secondary and primary prevention of coronary heart disease.
- To highlight the shift towards primary prevention in high-risk, presymptomatic individuals.
- To detail the risk factors necessary for calculating absolute myocardial infarction risk.
Summary:
- Controlled trials demonstrate the efficacy of antihypertensive and hypolipidemic drugs in CHD prevention.
- Secondary prevention focuses on target blood pressure and LDL-cholesterol levels in patients with existing CHD.
- Primary prevention strategies now target high-risk individuals using risk factor assessment (gender, age, family history, smoking, diabetes, lipids, blood pressure).
- Risk stratification employs epidemiological data-derived scores and algorithms to estimate annual myocardial infarction risk.
Impact:
- Informs clinical practice regarding evidence-based strategies for CHD prevention.
- Facilitates the identification and management of individuals at high risk for cardiovascular events.
- Supports the personalized approach to cardiovascular risk management through comprehensive risk factor evaluation.